NeuroVive Pharmaceutical AB Year End Report January - December 2019
STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 * NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroVive compl...
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
LUND, Sweden, Dec. 23, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chroni...
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License Agreement wi...
NeuroVive Pharmaceutical AB Interim Report January - September 2019
STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events July - September * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July-Septem...
NeuroVive Pharmaceutical AB Interim Report January - June 2019
STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important events April - June * The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. * The Supreme Court delivers it...
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
LUND, Sweden, 4 July 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333, NeuroVive's candidate drug for chronic treatment of genetic mitochondri...
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
LUND, Sweden, May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's ...
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq
Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the
Annual report for 2018 is now available on the company's website
www.neurovive.com
NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study
LUND, Sweden, March 19, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company's KL1333 phase Ia/b study has been screened and will be enrolled into the study. First subject first visit in NeuroVive's...
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
LUND, Sweden, Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awardedSEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova,Sweden's innovation agency, and the Swelife call, for i...
NeuroVive Receives KL1333 Clinical Trial Regulatory Approval
LUND, Sweden, Oct. 10, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory author...
NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI
LUND, Sweden, Oct. 4, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigat...
NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan
LUND, Sweden, Sept. 6 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) a...
NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia
LUND, Sweden, Aug. 28, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that scientists at the company's research partner the Children's Hospital ofPhiladelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TTDA), in total of$4,090...
NeuroVive Pharmaceutical AB Interim Report January - June 2018
STOCKHOLM, Aug. 21, 2018 /PRNewswire/ -- Important events January-June 2018 * NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately$60 million USD including any royalties. * NeuroVive ...
NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics
LUND, Sweden and PALO ALTO, Calif., June 19, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under Neuro...
Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, May 31, 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF),the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharma...
NeuroVive Pharmaceutical AB Interim Report January - March 2018
STOCKHOLM, May 22, 2018 /PRNewswire/ -- Successful rights issue Business operations Important events January – March 2018 * NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeti...
NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development
LUND, Sweden and SEOUL, South Korea, May 21, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced positive topline results after data base lock in the phase I single...
NeuroVive Initiates Collaboration With Leading US TBI Research Organization
LUND, Sweden, May 2, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a partnership with TRACK-TBI, a network of US-based world-leading TBI clinicians and researchers. The purpose of the network that NeuroVive now will be a part of intends to ...